Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T04:34:43.296Z Has data issue: false hasContentIssue false
  • English
  • Français

Direct versus indirect comparisons: A summary of the evidence

Published online by Cambridge University Press:  09 April 2008

Gerald Gartlehner  and
Charity G. Moore
Gerald Gartlehner
Affiliation:
Danube University Krems
Charity G. Moore
Affiliation:
University of Pittsburgh
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to provide a comprehensive summary and interpretation of the current evidence on the use and validity of statistical methods to conduct indirect comparisons of treatment effects.

Methods: A narrative review was conducted.

Results: Well-conducted methodological studies provide good evidence that adjusted indirect comparisons can lead to results similar to those from direct comparisons. The internal validity of several statistical methods to conduct indirect comparisons, therefore, has been established. Meta-regression, logistic regression, or adjusted indirect comparisons should be the methods of first choice. Unadjusted indirect comparisons are always unacceptable. Deciding whether to combine direct and indirect evidence will be a matter of informed judgment based on the similarities and dissimilarities of populations and interventions. Unverifiable assumptions with respect to the similarity of compared studies and low power are serious limitations of indirect comparisons.

Conclusions: In the absence of sufficient head-to-head evidence, adjusted indirect comparisons can be viewed as additional analytical tools to determine the comparative efficacy and effectiveness of competing interventions. Researchers who use indirect comparisons need to keep the limitations in mind.

Keywords

Indirect comparisonsAdjusted indirect comparisonsSummary of the evidence
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 24 , Issue 2 , April 2008 , pp. 170 - 177
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Alves, C, Cachola, I, Brandao, J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry. 1999;5:57–63.Google Scholar
2. Baker, SG, Kramer, BS. The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol. 2002;2:13.CrossRefGoogle Scholar
3. Bennie, EH, Mullin, JM, Martindale, JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56:229–237.Google ScholarPubMed
4. Boyer, P, Danion, JM, Bisserbe, JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics. 1998;13 (pt 2):157–169.CrossRefGoogle Scholar
5. Bucher, HC, Guyatt, GH, Griffith, LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691.CrossRefGoogle ScholarPubMed
6. Caldwell, DM, Ades, AE, Higgins, JP. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ. 2005;331:897–900.CrossRefGoogle ScholarPubMed
7. Costa e Silva, J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59:352–357.CrossRefGoogle ScholarPubMed
8. Cunningham, LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry. 1997;9:157–164.CrossRefGoogle ScholarPubMed
9. De Nayer, A, Geerts, S, Ruelens, L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002;5:115–120.CrossRefGoogle ScholarPubMed
10. Dierick, M, Ravizza, L, Realini, R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:57–71.CrossRefGoogle ScholarPubMed
11. Fava, M, Hoog, SL, Judge, RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002;22:137–147.CrossRefGoogle ScholarPubMed
12. Fava, M, Judge, R, Hoog, SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863–867.CrossRefGoogle ScholarPubMed
13. Glenny, AM, Altman, DG, Song, F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1–148.CrossRefGoogle ScholarPubMed
14. Gotzsche, PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA. 2006;295:1172–1174.CrossRefGoogle ScholarPubMed
15. Greene, WL, Concato, J, Feinstein, AR. Claims of equivalence in medical research: Are they supported by the evidence? Ann Intern Med. 2000;132:715–722.CrossRefGoogle ScholarPubMed
16. Higgins, JPT, Green, S, eds. Cochrane handbook for systematic reviews of interventions. 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.Google Scholar
17. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial. JAMA. 2002;287:1807–1814.CrossRefGoogle Scholar
18. Ioannidis, JP. Indirect comparisons: The mesh and mess of clinical trials. Lancet. 2006;368:1470–1472.CrossRefGoogle ScholarPubMed
19. Khan, A, Fabre, LF, Rudolph, R. Venlafaxine in depressed outpatients. Psychopharmacol Bull. 1991;27:141–144.Google ScholarPubMed
20. Kocsis, JH, Zisook, S, Davidson, J, et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes. Am J Psychiatry. 1997;154:390–395.Google ScholarPubMed
21. Kroenke, K, West, SL, Swindle, R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial. JAMA. 2001;286:2947–2955.CrossRefGoogle ScholarPubMed
22. Lu, G, Ades, AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105–3124.CrossRefGoogle ScholarPubMed
23. Lumley, T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313–2324.CrossRefGoogle ScholarPubMed
24. Lydiard, RB, Stahl, SM, Hertzman, M, et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry. 1997;58:484–491.CrossRefGoogle ScholarPubMed
25. McDonagh, MS CS. Drug class review on proton pump inhibitors. Drug effectiveness review project 2006. Available at: http://www.ohsu.edu/drugeffectiveness/reports/documents/PPIs %20Final%Report%u4%Unshaded.pdf. Accessed 11/2/2007.Google Scholar
26. Mehtonen, OP, Sogaard, J, Roponen, P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000;61:95–100.CrossRefGoogle ScholarPubMed
27. Mendels, J, Johnston, R, Mattes, J, et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993;29:169–174.Google Scholar
28. Nemeroff, CB, Thase, ME. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res. 2007;41:351–359.CrossRefGoogle ScholarPubMed
29. Newhouse, PA, Krishnan, KR, Doraiswamy, PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry. 2000;61:559–568.CrossRefGoogle ScholarPubMed
30. Olie, JP, Gunn, KP, Katz, E. A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression. Eur Psychiatry. 1997;12:34–41.CrossRefGoogle ScholarPubMed
31. Reimherr, FW, Byerley, WF, Ward, MF, et al. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull. 1988;24:200–205.Google ScholarPubMed
32. Reimherr, FW, Chouinard, G, Cohn, CK, et al. Antidepressant efficacy of sertraline: A double-blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51 (Suppl B):18–27.Google ScholarPubMed
33. Rudolph, RL, Feiger, AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999;56:171–181.CrossRefGoogle ScholarPubMed
34. Schatzberg, A, Roose, S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006;14:361–370.CrossRefGoogle ScholarPubMed
35. Schneider, LS, Nelson, JC, Clary, CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003;160:1277–1285.CrossRefGoogle ScholarPubMed
36. Sechter, D, Troy, S, Paternetti, S, et al. A double-blind compari-son of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry. 1999;14:41–48.CrossRefGoogle Scholar
37. Silverstone, PH, Ravindran, A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry. 1999;60:22–28.CrossRefGoogle ScholarPubMed
38. Sir, A, D'Souza, RF, Uguz, S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: Efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66:1312–1320.CrossRefGoogle ScholarPubMed
39. Song, F, Altman, DG, Glenny, AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ. 2003;326:472.CrossRefGoogle ScholarPubMed
40. Song, F, Glenny, AM, Altman, DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials. 2000;21:488–897.CrossRefGoogle ScholarPubMed
41. Thase, ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997;58:393–398.CrossRefGoogle ScholarPubMed
42. Tylee, A, Beaumont, G, Bowden, MW, et al. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry. 1997;3:51–58.Google Scholar
43. Tzanakaki, M, Guazzelli, M, Nimatoudis, I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol. 2000;15:29–34.CrossRefGoogle ScholarPubMed
44. Van Moffaert, M, Bartholome, F, Cosyns, P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol. 1995;10:393–405.CrossRefGoogle Scholar